Nektar Therapeutics
NASDAQ:NKTR

Watchlist Manager
Nektar Therapeutics Logo
Nektar Therapeutics
NASDAQ:NKTR
Watchlist
Price: 0.9078 USD 0.81% Market Closed
Market Cap: 167.5m USD
Have any thoughts about
Nektar Therapeutics?
Write Note

Nektar Therapeutics
Short-Term Investments

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Nektar Therapeutics
Short-Term Investments Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Short-Term Investments CAGR 3Y CAGR 5Y CAGR 10Y
Nektar Therapeutics
NASDAQ:NKTR
Short-Term Investments
$214.4m
CAGR 3-Years
-37%
CAGR 5-Years
-31%
CAGR 10-Years
0%
Johnson & Johnson
NYSE:JNJ
Short-Term Investments
$12.1B
CAGR 3-Years
-23%
CAGR 5-Years
-3%
CAGR 10-Years
-4%
Bristol-Myers Squibb Co
NYSE:BMY
Short-Term Investments
$204m
CAGR 3-Years
-55%
CAGR 5-Years
-37%
CAGR 10-Years
-22%
Pfizer Inc
NYSE:PFE
Short-Term Investments
$6B
CAGR 3-Years
-40%
CAGR 5-Years
-1%
CAGR 10-Years
-15%
Merck & Co Inc
NYSE:MRK
Short-Term Investments
$0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Eli Lilly and Co
NYSE:LLY
Short-Term Investments
$149.4m
CAGR 3-Years
59%
CAGR 5-Years
11%
CAGR 10-Years
-21%
No Stocks Found

Nektar Therapeutics
Glance View

Market Cap
167.5m USD
Industry
Pharmaceuticals

Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.

NKTR Intrinsic Value
0.6997 USD
Overvaluation 23%
Intrinsic Value
Price

See Also

What is Nektar Therapeutics's Short-Term Investments?
Short-Term Investments
214.4m USD

Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Short-Term Investments amounts to 214.4m USD.

What is Nektar Therapeutics's Short-Term Investments growth rate?
Short-Term Investments CAGR 10Y
0%

Over the last year, the Short-Term Investments growth was -30%. The average annual Short-Term Investments growth rates for Nektar Therapeutics have been -37% over the past three years , -31% over the past five years .

Back to Top